(Q34283096)

1 August 2017

1 reference

title

Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure (English)

1 reference

1 August 2017

1 reference

chronic heart failure

1 reference

Miller AB

1

1 reference

1 August 2017

Srivastava P

series ordinal

2

1 reference

1 August 2017

publication date

1 May 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

19

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

195-202, v

1 reference

Ectopic arrhythmia provoking action of aldosterone

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Evidence for a role of an intracardiac renin-angiotensin system in normal and failing hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

SPLANCHNIC EXTRACTION AND CLEARANCE OF ALDOSTERONE IN SUBJECTS WITH MINIMAL AND MARKED CARDIAC DYSFUNCTION

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Production of aldosterone in isolated rat blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

Interactions of mineralocorticoids and pressor agents in vascular smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8651%2805%2970207-1

7 January 2021

10.1016/S0733-8651(05)70207-1

Identifiers

DOI

1 reference

release_ly6fivc7gfbl3n3sld3cgmucoi

1 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ly6fivc7gfbl3n3sld3cgmucoi

24 November 2022

mapped directly with Wikidata item

1 reference